© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 26, 2021
Richard Anderson, MD, PhD, discusses ways to preserve fertility in patients who are undergoing or have complete treatment for lymphoma.
November 23, 2021
Venetoclax in combination with EPOCH-R is safe and shows preliminary efficacy in patients with aggressive B-cell lymphoma.
November 19, 2021
Patrick Connor Johnson, MD, discusses what physicians take into consideration when considering third-line treatment options in diffuse large B-cell lymphoma.
November 17, 2021
Michael Wang, MD, professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center, discusses the FDA approval of lisocabtagene maraleucel.
November 16, 2021
Subasumstat was found to have a manageable safety profile along with preliminary anti-tumor activity in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma.
November 15, 2021
Epcoritamab should be evaluated further after positive phase 1/2 results showing the agent was safe with preliminary antitumor activity.
November 01, 2021
The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.
October 28, 2021
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss possible future developments with BTKi as therapy options in B-cell lymphomas.
Drs Shadman and Cohen introduce new data concerning a third-generation BTK inhibitor, pirtobrutinib, and discuss unmet needs in the B-cell malignancy landscape.
October 21, 2021
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, share their preferences regarding BTK-targeted treatment in B-cell malignancies.